WO2014163402A1 - 인삼 열매 추출물을 함유하는 여성 건강 및 삶의 질 개선용 조성물 - Google Patents
인삼 열매 추출물을 함유하는 여성 건강 및 삶의 질 개선용 조성물 Download PDFInfo
- Publication number
- WO2014163402A1 WO2014163402A1 PCT/KR2014/002853 KR2014002853W WO2014163402A1 WO 2014163402 A1 WO2014163402 A1 WO 2014163402A1 KR 2014002853 W KR2014002853 W KR 2014002853W WO 2014163402 A1 WO2014163402 A1 WO 2014163402A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- life
- ginseng fruit
- ginseng
- fruit extract
- Prior art date
Links
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 86
- 241000208340 Araliaceae Species 0.000 title claims abstract description 85
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 85
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 85
- 239000000284 extract Substances 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 230000036541 health Effects 0.000 title claims abstract description 23
- 235000021028 berry Nutrition 0.000 title abstract 2
- 230000036299 sexual function Effects 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 235000013399 edible fruits Nutrition 0.000 claims description 70
- 206010016256 fatigue Diseases 0.000 claims description 14
- 230000001737 promoting effect Effects 0.000 claims description 5
- 230000009323 psychological health Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000003836 peripheral circulation Effects 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 15
- 229940107131 ginseng root Drugs 0.000 description 13
- 230000037406 food intake Effects 0.000 description 10
- 229930182494 ginsenoside Natural products 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 230000000994 depressogenic effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 229940089161 ginsenoside Drugs 0.000 description 6
- 230000036642 wellbeing Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010027304 Menopausal symptoms Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035946 sexual desire Effects 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004092 self-diagnosis Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000030247 mild fever Diseases 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 1
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000026843 stiff neck Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
Definitions
- the present invention relates to a composition containing ginseng fruit extract as an active ingredient to improve women's health and quality of life, and more particularly, to improve the overall psychological and physical health of women, and to improve female sexual function and sexual life satisfaction. And compositions for improving overall quality of life (QOL).
- QOL overall quality of life
- Ginseng (Panax ginseng CA Meyer) is a plant belonging to the genus Ogapiaceae ginseng, which has been used for more than 2,000 years in Korea, China, Japan, etc., and has been used to prevent disease and prolong life.
- ginseng on the central nervous system, anti-carcinogenic, anti-cancer, immune-modulatory, antidiabetic, hepatic anti-inflammatory effect, cardiovascular disorders, anti-arteriosclerosis, blood pressure control, menopausal disorders , Effects on osteoporosis, anti-stress, anti-fatigue, antioxidant activity, anti-aging effects are known (latest ginseng 'components and efficacy', Korea Ginseng and Tobacco Research Institute, 56-112, 1996).
- Ginsenoside a representative physiologically active ingredient of ginseng, is distributed evenly on the ground and underground parts of ginseng. Especially, ginsenoside content and composition are different depending on the parts such as ginseng root (root), ginseng leaf, and ginseng fruit. (Attele AS et al, Biochem Pharmacol, 58; 1685-1693, 1999.). In particular, ginseng fruit has the content and composition of ginsenosides and other ginsenosides, and it is reported that the ginseng fruit has better results than ginseng root in antidiabetic effect (Dey L. et al., Phytomedicine , 10; 600-605, 2003.).
- the present inventors studied various physiological activities of ginseng fruit extract of ground ginseng in addition to the ginseng root which is the underground part of ginseng, and the ginseng fruit extract improves general body function and menopausal symptoms by different ingredients and composition from general ginseng and red ginseng
- the present invention has been found to be effective in improving female sexual function and sexual life satisfaction.
- an object of the present invention is to provide a composition capable of increasing the female health index, and in particular, improving the sexual function, to increase the happiness and quality of life of women.
- the present invention provides a composition for promoting female body health containing ginseng fruit extract as an active ingredient.
- the present invention also provides a psychological health promotion composition containing the ginseng fruit extract as an active ingredient.
- the present invention provides a composition for improving female sexual function containing ginseng fruit extract as an active ingredient.
- Ginseng fruit extract of the present invention can not only improve the overall physical function and menopausal symptoms, but also can improve the sexual function and sexual life satisfaction of women.
- 1 is a graph showing the results of analyzing ginsenoside components of the ginseng fruit extract and ginseng extract of Example 1.
- Figure 2 shows the results of evaluating the overall physical health improvement according to the intake of ginseng fruit extract.
- Figure 3 shows the results of evaluating the chronic fatigue improvement according to the intake of ginseng fruit extract.
- 4 is a graph showing the correlation between PGWBI and FSFI index.
- the present invention relates to a composition that can improve the quality of life of women, and more specifically, it is identified through the Psychological General Well-Being Index (PGWBI) and the Female Sexual Function Index (FSFI). As can be seen relates to a composition capable of improving the physical and psychological health and sexual function of a woman.
- PGWBI General Well-Being Index
- FSFI Female Sexual Function Index
- composition according to the present invention can improve the overall physical health of a woman by providing an improvement effect such as peripheral blood circulation, chronic fatigue, and in particular can help to improve menopausal symptoms.
- composition according to the present invention can improve psychological health by giving life to life while reducing mental anxiety, depression and the like and improving self-control.
- composition according to the present invention can improve the sexual life by improving the female sexual function.
- composition according to the present invention is characterized by mixing the ginseng fruit extract in an amount of 1 to 100% by weight, based on the total weight of the composition.
- Ginseng fruit extract used in the present invention is extractable from all parts including the skin, pulp and the like of ginseng fruit.
- the ginseng fruit extract used in the invention may be an extract obtained from the flesh and skin of the ginseng fruit except for the seed, may be an extract obtained only from the flesh of the ginseng fruit, or may be an extract obtained only from the skin of the ginseng fruit. have.
- the extraction method is not particularly limited as long as it is a method commonly used in the art, for example, may be prepared by extraction with water or a lower alcohol, for example methanol, ethanol and the like.
- the composition may be formulated as a pharmaceutical composition or food composition in the form of tablets, pills, tablets, capsules, granules, powders, ointments, drinks or injections.
- compositions of the present invention can be prepared in pharmaceutical formulations according to conventional methods.
- the active ingredient is mixed or diluted with the carrier or enclosed in a carrier in the form of a container.
- the carrier when used as a diluent, it may be a solid, semisolid or liquid substance which acts as a carrier, excipient or medium for the active ingredient.
- the formulation may be in the form of tablets, pills, powders, sachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, sterile injectables, sterile powders and the like.
- Suitable carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propyl Hydroxybenzoate, talc, magnesium stearate and mineral oil.
- the formulation may further comprise fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives and the like.
- Compositions of the present invention may be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
- composition of the present invention may be administered through several routes including oral, transdermal, subcutaneous, intravenous, abdominal, muscle, topical application, patch and iontophoresis, of which topical application and oral administration are preferred. Do.
- a typical daily dosage of the active compound may range from 1 to 100 mg / kg body weight, preferably 5 to 70 mg / kg body weight, and may be administered once or in several doses.
- the actual dosage of the active ingredient should be determined in light of several relevant factors such as the disease to be treated, the route of administration, the age, sex and weight of the patient, and the severity of the disease, and therefore the dosage may be determined in any way. Nor does it limit the scope of the present invention.
- the ginseng fruit dried raw material was prepared through daylight drying or hot air drying.
- the raw ginseng fruit was harvested and the seeds were separated and removed, and the pulp, juice and rind of the ginseng fruit were collected and used as the ginseng fruit raw material.
- ginseng fruit raw material ie, flesh, juice and rind mixture
- extraction at room temperature or reflux, followed by filtration and concentration under reduced pressure to obtain 30 g of ginseng fruit extract.
- Example 1 Except for using ginseng root (root) instead of ginseng fruit in Example 1 was prepared in the same manner as in Example 1.
- Ginsenoid Ginseng Saponin
- Ginseng fruit and ginseng root extracts were prepared in Examples 1 and 2, and Comparative Example 1, respectively, and these extracts were treated with ether to remove fat-soluble components, followed by extracting and concentrating irradiated ponponin with butanol (BuOH). Ginsenoside component analysis was performed through, and the results are shown in FIG. 1 and Table 1 below.
- Example 1 Example 2 Comparative Example 1 Irradiated Ponin Content (Dry Weight) 33.42% 31.08 16.70% PD / PT ratio 0.73 0.69 3.23
- the ginseng fruit extract prepared in Examples 1 and 2 has about 2 times the content of the ginseng root extract prepared in Comparative Example 1 in the content of the irradiated phonynin, ginsenoside PD ( Protopanaxadiol)-"Ginsenosides Rb1, Rb2, Rc and Rd” and PT (Protopanaxatriol) system- "Ginsenosides Re, Rg1 and Rg2"
- ginsenoside PD Protopanaxadiol
- PT Protopanaxatriol
- Example 2 In order to distinguish that the ginseng fruit extract prepared in Example 1 has the characteristics of 'fruit' different from the ginseng root, mineral components including vitamins were analyzed, and the results are shown in Table 2 below.
- Example 1 Example 2 Potassium (mg / 100g) 5865.57 4977.50 Magnesium (mg / 100g) 354.38 297.54 Calcium (mg / 100g) 819.26 914.22 Zinc (mg / 100g) 178.49 201.25 Iron (mg / 100g) 59.31 52.11 Vit.A (ug / 100g, RE) 213.11 145.85 Phosphorus (mg / 100g) 187.17 156.95 Vit.B1 (mg / 100g) 12.29 10.09 Vit.B2 (mg / 100g) 8.45 5.05 Vit.B6 (mg / 100g) 10.50 15.44 Vit.C (mg / 100g) 4.91 7.13 Vit.E (mg / 100g, ⁇ -TE) 23.61 31.25 Vit.K ( ⁇ / 100g) 232.12 129.82 Niacin (mg / /
- the ginseng fruit used in the present invention contains more ginseng saponin than the ginseng root, and at the same time, the nature of the composition of saponin is opposite to that of the ginseng root.
- the nature of the composition of saponin is opposite to that of the ginseng root.
- the ginseng fruit extract is expected to show a different potency from the ginseng root extract and its components and their content significantly different.
- the extract of the dried ginseng fruit (Example 1) and the non-dried extract of the raw ginseng fruit (Example 2) the contained ingredients and their contents were found to be similar to show similar efficacy. It can be predicted.
- Example 2 Prepared by the method of Example 1 to prepare a 700mg tablet (50% ginseng fruit 350mg; excipients, crystalline cellulose, 50%, etc.) containing 50% ginseng fruit extract with a ginsenoside-Re content of at least 10%, This was used as a test product.
- the subjects were 18 females in their 20s and 30s and 25 females in their 40s and 50s (of which 28 were married).
- Two tablets were taken once a day with water twice a day for 4 weeks.
- the questionnaire was surveyed before and after ingestion for changes in symptoms and discomforts related to the general health.
- the survey evaluation method was as follows. The evaluation method was conducted as a pre- and post-intake self-assessment (response) of ginseng fruit extract in a questionnaire consisting of four areas. In area 1, the number of items experienced for uncomfortable symptoms related to overall physical health was compared before and after ingestion of ginseng fruit extract. In comparison, area 2 was evaluated for the symptoms of chronic fatigue. The symptom was to record the severity with a score of 0-3 points. In area 3, students should record PGWBI (quality of life; assessment of physical and mental health, stress, etc. that they are experiencing), and in area 4, record FSFI (evaluation of female sexual function / sexual life satisfaction). The effects of ginseng fruit extract on female health were evaluated.
- PGWBI quality of life; assessment of physical and mental health, stress, etc. that they are experiencing
- FSFI evaluation of female sexual function / sexual life satisfaction
- the Psychological General Well-Being Index (PGWBI) is a health-related QOL developed by Harold Dupuy (1984, USA) to express and measure the degree of well-being and distress experienced by individuals. (Quality of Life) It consists of 22 items. It was introduced in Europe in the 1990s and applied in various languages and countries, and the HRQoL that an individual feels was expressed in six areas: “Anxiety, Vitality, Depressed mood, Self-control, Assessing positive well-being, general health.
- the six areas described above were evaluated for changes before and after the intake of ginseng fruit extract, and scores of 0 to 5 points for each area were obtained, and the sum of these scores was the PGWBI score. It was set as (0-30 points).
- a score of zero for an item means that the quality of life is "low” or “bad", and as you move to a score of five, the quality of life is "high” or "good.”
- the average of the scores of each item in each area was calculated and their total scores were measured to measure the overall quality of life.
- the FSFI Male Sexual Function Index
- Dr. Raymond Rosen for clinical research purposes to measure female sexual function and sexual life satisfaction (Bayer AG, Zonagen Inc. funding). "Sexual Desire, Sexual Stimulation, Arousal, Female Lubrication, Orgasm, Sexual Satisfaction, Pain in Sex”.
- Specific evaluation items are as follows. Among them, the question related to sexual desire is number one, the question related to excitement is number two, the question related to orgasm is three, and the question related to satisfaction is four.
- ginseng fruit extract after taking ginseng fruit extract, the FSFI index improved by 16.2% from 4.21 to 4.89.
- ginseng fruit extracts can improve the quality of life by improving the FSFI index by having an improvement effect in the areas of excitement, orgasm, and satisfaction.
- the PGWBI assessment which recognizes one's own health status and the state of mental stress
- the FSFI assessment which measures women's sexual function and sexual life satisfaction, were proportional to each other. This is shown in FIG. 4.
- the happiness index of women can be expressed through the degree of improvement of quality of life such as PGWBI and FSFI.
- PGWBI, FSFI and two main indexes are high both before and after improvement by the intake of phosphate extract as shown in FIG. It can be judged that it is an essential evaluation factor by showing correlation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
실시예 1 | 실시예 2 | 비교예 1 | |
조사포닌함량(건조중량) | 33.42% | 31.08 | 16.70% |
PD/PT 비율 | 0.73 | 0.69 | 3.23 |
성분 | 함량 | 성분 | 함량 | ||
실시예1 | 실시예2 | 실시예1 | 실시예2 | ||
칼륨(mg/100g) | 5865.57 | 4977.50 | 마그네슘(mg/100g) | 354.38 | 297.54 |
칼슘(mg/100g) | 819.26 | 914.22 | 아연(mg/100g) | 178.49 | 201.25 |
철(mg/100g) | 59.31 | 52.11 | Vit.A(ug/100g, RE ) | 213.11 | 145.85 |
인(mg/100g) | 187.17 | 156.95 | Vit.B1(mg/100g) | 12.29 | 10.09 |
Vit.B2(mg/100g) | 8.45 | 5.05 | Vit.B6(mg/100g) | 10.50 | 15.44 |
Vit.C(mg/100g) | 4.91 | 7.13 | Vit.E(mg/100g, α-TE) | 23.61 | 31.25 |
Vit.K(㎍/100g) | 232.12 | 129.82 | 나이아신(mg/100g, NE) | 5.76 | 2.01 |
판토텐산(mg/100g) | 5.87 | 6.15 | 엽산(㎍/100g) | 349.97 | 423.35 |
번호 | 질문 | 전혀 없다 | 2주에 한 번 정도 | 주 1회 정도 | 자주 증상이 있음 |
1 | 아무리 쉬어도 피로가 사라지지 않는다 | ||||
2 | 몸에 미열이나 오한기가 있다 | ||||
3 | 전신의 근육이 그냥 아프면서 무겁다 | ||||
4 | 깊은 잠을 자지 못한다 | ||||
5 | 머리 회전이 예전 같지 못하다 | ||||
6 | 마음이 자주 우울하다 | ||||
7 | 두통이 심하다 | ||||
8 | 목이 붓고 아프면서 이물감이 있다 | ||||
9 | 매사에 자주 신경질적이다 | ||||
10 | 온 몸에 힘이 쭉 빠진다 | ||||
11 | 뒷목이 뻣뻣하다 | ||||
12 | 눈이 자꾸 자꾸 침침해진다 | ||||
13 | 소변을 자주 보러 나간다 | ||||
14 | 배속이 울렁거리면서 어지럽다 | ||||
15 | 맥박이 빨라진다 | ||||
16 | 눈이 뻑뻑하다 | ||||
17 | 입안이 마른다 | ||||
18 | 변이 묽거나 굳는 등 불규칙하다 | ||||
19 | 손마디가 붓는다 | ||||
20 | 잠을 잘 때 땀이 잘 난다 | ||||
21 | 얼굴이 화끈거리면서 붉게 달아 오른다 |
평균 | 표준편차 | ||
섭취 전 | 18.19 | 13.03 | 만성피로지수평균 6.10 개선 |
섭취 후 | 12.09 | 10.70 |
항목 | 범위 | 섭취 전 평균±S.D | 섭취 후 평균±S.D | 차이 | P-값 |
불안 | 0~5 | 3.86 ± 1.28 | 4.35 ± 0.84 | 0.49 | 0.013 |
생동감 | 0~5 | 2.63 ± 0.98 | 3.21 ± 0.86 | 0.58 | 0.001 |
우울 | 0~5 | 3.14 ± 0.94 | 3.79 ± 0.89 | 0.65 | 0.001 |
자기조절 | 0~5 | 2.02 ± 1.28 | 2.37 ± 1.25 | 0.35 | 0.092 |
안녕감 | 0~5 | 2.09 ± 1.29 | 2.84 ± 1.34 | 0.74 | 0.001 |
일반적 건강 | 0~5 | 2.84 ± 1.15 | 3.72 ± 0.77 | 0.88 | 0.000 |
PGWBI 점수 | 0~30 | 16.58 ± 4.59 | 20.28 ± 4.15 | 3.70 | 0.000 |
영역 | 범위 | 가중치 | 섭취 전 평균±S.D | 섭취 후 평균±S.D | 차이 | P-값 |
성욕 | 1~5 | 0.6 | 2.32 ± 1.19 | 2.46 ± 0.88 | 0.14 | 0.381 |
흥분 | 0~5 | 0.3 | 2.25 ± 1.55 | 2.79 ± 1.37 | 0.54 | 0.033 |
오르가즘 | 0~5 | 0.4 | 2.46 ± 1.95 | 3.04 ± 1.64 | 0.57 | 0.033 |
만족도 | 1~5 | 0.4 | 2.89 ± 1.62 | 3.39 ± 1.45 | 0.50 | 0.06 |
FSFI 점수 | 1~8.5 | 4.21 ± 2.34 | 4.89 ± 1.90 | 0.68 | 0.031 |
Claims (14)
- 인삼 열매 추출물을 유효성분으로 함유하는, 여성 삶의 질 개선용 조성물.
- 제1항에 있어서, 상기 조성물은 여성 신체 건강 증진용임을 특징으로 하는 조성물.
- 제2항에 있어서, 상기 조성물은 말초 순환 개선용임을 특징으로 하는 조성물.
- 제2항에 있어서, 상기 조성물은 만성 피로 개선용임을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 조성물은 심리적 건강 증진용임을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 조성물은 여성 성기능 개선용임을 특징으로 하는 조성물.
- 제1항 내지 제6항 중 어느 한 항은 식품 조성물임을 특징으로 하는 조성물.
- 제1항 내지 제6항 중 어느 한 항은 약학 조성물임을 특징으로 하는 조성물.
- 인삼 열매 추출물을 유효성분으로 함유하는 조성물의 여성 삶의 질 개선용으로서의 용도.
- 제9항에 있어서, 상기 조성물은 여성 신체 건강 증진용임을 특징으로 하는 용도.
- 제10항에 있어서, 상기 조성물은 말초 순환 개선용임을 특징으로 하는 용도.
- 제10항에 있어서, 상기 조성물은 만성 피로 개선용임을 특징으로 하는 용도.
- 제9항에 있어서, 상기 조성물은 심리적 건강 증진용임을 특징으로 하는 용도.
- 제9항에 있어서, 상기 조성물은 여성 성기능 개선용임을 특징으로 하는 용도.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016506238A JP6655005B2 (ja) | 2013-04-02 | 2014-04-02 | 薬用人参の実エキスを含有する女性の健康及び生活の質改善用組成物 |
US14/779,599 US10383904B2 (en) | 2013-04-02 | 2014-04-02 | Composition for improving health and quality of life of women containing ginseng berry extract |
EP14779978.7A EP2982377B1 (en) | 2013-04-02 | 2014-04-02 | Ginseng berry extract for use in alleviating menopausal symptoms |
CN201480003596.9A CN104870003A (zh) | 2013-04-02 | 2014-04-02 | 含有人参果提取物的用于改善女性健康和生活质量的组合物 |
HK16101573.5A HK1213491A1 (zh) | 2013-04-02 | 2016-02-12 | 含有人參果提取物的用於改善女性健康和生活質量的組合物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130035810 | 2013-04-02 | ||
KR10-2013-0035810 | 2013-04-02 | ||
KR10-2014-0039272 | 2014-04-02 | ||
KR1020140039272A KR20140120280A (ko) | 2013-04-02 | 2014-04-02 | 인삼 열매 추출물을 함유하는 여성 건강 및 삶의 질 개선용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014163402A1 true WO2014163402A1 (ko) | 2014-10-09 |
Family
ID=51992244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/002853 WO2014163402A1 (ko) | 2013-04-02 | 2014-04-02 | 인삼 열매 추출물을 함유하는 여성 건강 및 삶의 질 개선용 조성물 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10383904B2 (ko) |
EP (1) | EP2982377B1 (ko) |
JP (1) | JP6655005B2 (ko) |
KR (2) | KR20140120280A (ko) |
CN (2) | CN104870003A (ko) |
HK (1) | HK1213491A1 (ko) |
WO (1) | WO2014163402A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102262306B1 (ko) * | 2013-07-04 | 2021-06-09 | (주)아모레퍼시픽 | 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물 |
KR102336131B1 (ko) * | 2015-04-02 | 2021-12-07 | (주)아모레퍼시픽 | 인삼 열매 추출물을 함유하는 난소 노화 개선용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050076057A (ko) * | 2004-01-19 | 2005-07-26 | 대한민국(전남대학교총장) | 진세노사이드를 유효성분으로 함유하는 여성 성기능 개선제 |
KR20070051934A (ko) * | 2007-04-06 | 2007-05-18 | 고붕경 | 인삼 사포닌 Rg2의 추출방법 및 그 추출물을 포함하는 의약조성물과 그 용도 |
KR20080094540A (ko) * | 2007-04-20 | 2008-10-23 | (주)아모레퍼시픽 | 인삼 열매 추출물을 함유하는 피부 외용제 조성물 |
KR20110079564A (ko) * | 2009-12-31 | 2011-07-07 | (주)아모레퍼시픽 | 인삼 열매 추출물을 함유하는 미토콘드리아 활성화를 위한 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6007824A (en) * | 1998-07-09 | 1999-12-28 | Duckett; Melvin J. | Natural composition and method for the treatment of sexual dysfunction |
CN1191071C (zh) * | 2002-12-28 | 2005-03-02 | 杨淑玲 | 人参皂苷单体配伍提高性功能的产品 |
KR20080104600A (ko) * | 2007-05-28 | 2008-12-03 | (주)아모레퍼시픽 | 인삼 열매 추출물을 함유하는 혈행촉진, 혈관신생촉진, 및허혈성 심질환 치료용 조성물 |
KR20080105470A (ko) * | 2007-05-31 | 2008-12-04 | (주)아모레퍼시픽 | 인삼 열매 추출물을 함유하는 비만 예방 및 개선용 식품조성물 |
KR101593618B1 (ko) * | 2009-05-26 | 2016-02-15 | (주)아모레퍼시픽 | 사포닌의 생체 이용률 증진 조성물 |
KR102200012B1 (ko) * | 2013-04-02 | 2021-01-08 | (주)아모레퍼시픽 | 인삼열매 추출물을 포함하는 뇌 활성화 조성물 |
-
2014
- 2014-04-02 WO PCT/KR2014/002853 patent/WO2014163402A1/ko active Application Filing
- 2014-04-02 JP JP2016506238A patent/JP6655005B2/ja active Active
- 2014-04-02 KR KR1020140039272A patent/KR20140120280A/ko not_active IP Right Cessation
- 2014-04-02 US US14/779,599 patent/US10383904B2/en active Active
- 2014-04-02 EP EP14779978.7A patent/EP2982377B1/en active Active
- 2014-04-02 CN CN201480003596.9A patent/CN104870003A/zh active Pending
- 2014-04-02 CN CN202111270304.6A patent/CN114053320A/zh active Pending
-
2016
- 2016-02-12 HK HK16101573.5A patent/HK1213491A1/zh unknown
-
2021
- 2021-03-16 KR KR1020210033950A patent/KR20210037626A/ko not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050076057A (ko) * | 2004-01-19 | 2005-07-26 | 대한민국(전남대학교총장) | 진세노사이드를 유효성분으로 함유하는 여성 성기능 개선제 |
KR20070051934A (ko) * | 2007-04-06 | 2007-05-18 | 고붕경 | 인삼 사포닌 Rg2의 추출방법 및 그 추출물을 포함하는 의약조성물과 그 용도 |
KR20080094540A (ko) * | 2007-04-20 | 2008-10-23 | (주)아모레퍼시픽 | 인삼 열매 추출물을 함유하는 피부 외용제 조성물 |
KR20110079564A (ko) * | 2009-12-31 | 2011-07-07 | (주)아모레퍼시픽 | 인삼 열매 추출물을 함유하는 미토콘드리아 활성화를 위한 조성물 |
Non-Patent Citations (4)
Title |
---|
ATTELE AS ET AL., BIOCHEM PHARMACOL, vol. 58, 1999, pages 1685 - 1693 |
COLEMAN. C. I. ET AL.: "THE EFFECTS OF PANAX GINSENG ON QUALITY OF LIFE", JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS., vol. 23, 2003, pages 5 - 15, XP055284558 * |
DEY L. ET AL., PHYTOMEDICINE, vol. 10, 2003, pages 600 - 605 |
See also references of EP2982377A4 |
Also Published As
Publication number | Publication date |
---|---|
KR20210037626A (ko) | 2021-04-06 |
EP2982377A4 (en) | 2016-10-26 |
EP2982377A1 (en) | 2016-02-10 |
US20160058811A1 (en) | 2016-03-03 |
CN114053320A (zh) | 2022-02-18 |
HK1213491A1 (zh) | 2016-07-08 |
KR20140120280A (ko) | 2014-10-13 |
JP6655005B2 (ja) | 2020-02-26 |
JP2016515613A (ja) | 2016-05-30 |
EP2982377B1 (en) | 2023-06-07 |
CN104870003A (zh) | 2015-08-26 |
US10383904B2 (en) | 2019-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012124888A2 (en) | Composition comprising the extract of herbal combination for preventing or treating diabetic peripheral neuropathy | |
WO2020235928A1 (ko) | 흑삼 추출물을 포함하는 항인플루엔자 바이러스 조성물, 호흡기 질환 치료용 조성물 및 항노화 조성물 | |
WO2015160219A1 (ko) | 피스타시아 웨인마니폴리아 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 만성폐쇄성 폐질환(copd) 예방 또는 치료용 약학적 조성물 | |
WO2009104902A2 (en) | Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising panax species plant leaves extract or processed panax species plant leaves extract, or mixture of the both | |
WO2020040462A1 (ko) | 식물 추출물을 유효성분으로 하는 미세먼지에 의해 유도된 호흡기질환 예방 또는 치료용 조성물 | |
WO2018208094A2 (en) | A composition comprising a combined herb extract of salvia plebia and red ginseng as active ingredients for preventing or treating a respiratory inflammation and the use thereof | |
WO2021049864A1 (ko) | 두릅나무 추출물을 함유하는 안구건조증 개선용 조성물 | |
WO2014163402A1 (ko) | 인삼 열매 추출물을 함유하는 여성 건강 및 삶의 질 개선용 조성물 | |
WO2012093787A2 (ko) | 플로로글루시놀, 플로로탄닌 또는 갈조류 추출물을 포함하는 가바 a형-벤조다이아제핀 수용체 활성용 조성물 및 불안 완화, 경련 개선, 진정 작용, 및 수면 유도 및 개선용 조성물 | |
WO2021107547A1 (ko) | 호흡기 질환의 예방, 개선 또는 치료용 조성물 | |
WO2010090498A2 (ko) | 이고들빼기 추출물, 이의 분획물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 간 기능 개선용 약학적 조성물 및 간 기능 개선용 건강기능 식품조성물 | |
WO2016129902A1 (ko) | 번아웃증후군의 예방, 개선 또는 치료용 조성물 | |
WO2017183924A1 (ko) | 단풍나무 잎 추출물을 포함하는 안구건조증의 예방 또는 치료용 조성물 | |
EP3062807A1 (en) | Compositions comprising a viola herba extract, or an extract of viola herba, persicae semen, cinnamomi ramulus, and glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity | |
WO2023106884A1 (ko) | 사철쑥 및 죽순 추출물을 포함하는 장질환 예방 또는 치료용 조성물 | |
WO2015002430A1 (ko) | 피스타시아 웨인마니폴리아 추출물 또는 이의 분획물을 포함하는 천식의 예방 또는 치료용 약학 조성물 | |
WO2018221922A1 (ko) | 황련 추출물을 함유하는 근육관련 질환의 예방 및 치료용 조성물 및 이의 용도 | |
WO2009104913A2 (en) | Composition comprising an extract of mixed herbs with lonicera japonica thunb and anemarrhena asphodeloides bunge for preventing and treating arthritic diseases | |
WO2014109587A1 (ko) | 천연 추출물을 포함하는 당뇨합병증 또는 혈관부종의 예방 또는 치료용 약학적 조성물 및 건강기능식품 조성물 | |
WO2016175589A2 (ko) | 혼합 생약 추출물을 함유하는 호흡기 질환 예방 또는 치료용 약학적 조성물 | |
WO2021206455A1 (ko) | 멜리사엽 분획 추출물 및 이를 포함하는 신규한 약학적 조성물 | |
WO2021002642A1 (ko) | 뱀독을 포함하는 류마티스 관절염의 예방 또는 치료용 조성물 | |
WO2019172566A1 (ko) | 이오논을 유효성분으로 함유하는 항스트레스제, 항우울제 또는 항불안제 조성물 | |
WO2010143825A2 (en) | Anti-arthritic agent using cyathula officinalis | |
WO2023075489A1 (ko) | 황칠나무 수액 추출물 또는 이의 유래 화합물을 유효성분으로 포함하는 대사증후군 관련 질환의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14779978 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14779599 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014779978 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016506238 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |